RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA CongressBusiness Wire • 09/13/23
Lineage to Present at 2023 International Spinal Research Trust Network MeetingBusiness Wire • 09/11/23
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna TherapeuticsBusiness Wire • 09/06/23
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment ConferenceBusiness Wire • 08/29/23
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 08/10/23
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023Business Wire • 08/03/23
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung CancerBusiness Wire • 07/24/23
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/11/23
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023Business Wire • 05/04/23
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular DegenerationBusiness Wire • 04/26/23
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor SymposiumBusiness Wire • 03/30/23
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation SummitBusiness Wire • 03/20/23
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/09/23
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.Business Wire • 03/06/23
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023Business Wire • 03/02/23
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology IndicationsBusiness Wire • 02/22/23
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing LossBusiness Wire • 02/08/23